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ABSTRACT
Purpose: Taxane-induced peripheral neuropathy (TIPN) is one of the most 
important survivorship issues for cancer patients. African Americans (AA) have 
previously been shown to have an increased risk for this toxicity. Germline predictive 
biomarkers were evaluated to help identify a priori which patients might be at 
extraordinarily high risk for this toxicity.
Experimental design: Whole exome sequencing was performed using germline 
DNA from 213 AA patients who received a standard dose and schedule of paclitaxel in 
the adjuvant, randomized phase III breast cancer trial, E5103. Cases were defined as 
those with either grade 3-4 (n=64) or grade 2-4 (n=151) TIPN and were compared 
to controls (n=62) that were not reported to have experienced TIPN. We retained for 
analysis rare variants with a minor allele frequency <3% and which were predicted 
to be deleterious by protein prediction programs. A gene-based, case-control analysis 
using SKAT was performed to identify genes that harbored an imbalance of deleterious 
variants associated with increased risk of TIPN. 
Results: Five genes had a p-value < 10-4 for grade 3-4 TIPN analysis and three 
genes had a p-value < 10-4 for the grade 2-4 TIPN analysis. For the grade 3-4 
TIPN analysis, SET binding factor 2 (SBF2) was significantly associated with TIPN 
(p-value=4.35 x10-6).  Five variants were predicted to be deleterious in SBF2. Inherited 
mutations in SBF2 have previously been associated with autosomal recessive, Type 
4B2 Charcot-Marie-Tooth (CMT) disease.
Conclusion: Rare variants in SBF2, a CMT gene, predict an increased risk of TIPN 
in AA patients receiving paclitaxel. 
INTRODUCTION 
The taxanes are commonly employed 
chemotherapeutic agents for a variety of malignancies.
[1] While improving disease-specific outcomes, they 
also can impart substantial morbidity. The most common 
and particularly troublesome toxicity is taxane-induced 
peripheral neuropathy (TIPN).[2] TIPN can be severe, 
limit function, cause pain, and may be irreversible. 
Currently, there are no agents that have been proven to 
prevent this toxicity and very few have demonstrated 
benefit in improving symptoms after the toxicity has 
occurred.[3] Several demographic variables have been 
shown to increase the risk of TIPN, including: older 
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age, obesity, and the dose and schedule of the taxane.[4] 
Previously, we found that patients who were genetically 
defined as African American (AA) had a markedly 
increased risk for both moderate (grade 2-4) and severe 
(grade 3-4) TIPN.[5] Despite these findings, much 
ambiguity remains as to which patients might be at the 
highest risk for TIPN. Importantly, TIPN is not correlated 
with superior outcomes in the curative setting.[6] Thus, 
understanding which AA patients might be at exceptional 
risk would be beneficial for proper counseling and 
therapeutic decision-making when considering the risk to 
benefit ratio for a specific clinical scenario. 
Prior correlative studies have been conducted 
to uncover inherited genetic markers which confer an 
increased risk for TIPN.[7-15] The majority of these 
studies have focused on patients of European ancestry 
(EA) due to the under-representation of AA patients in 
many clinical studies across the United States. In addition, 
most studies have focused on the role of common variants, 
typically those with a minor allele frequency (MAF) 
greater than 3%. Recent advances in genomic technology 
has allowed for evaluation of rare coding (exonic) variants 
at a reasonable speed and price. The rare-variant, common 
disease hypothesis posits that rare coding variants are 
more likely to impose a larger effect on risk than common 
(typically non-exonic) variants.[16, 17] Discovery of 
variants with large effect size is clinically more beneficial 
and has greater statistical power when interrogating data 
sets of modest sample size. In this study we used whole 
exome sequencing (WES) to test the hypothesis that rare 
coding variants impact the risk of TIPN for AA patients. 
RESULTS
Significant covariates for TIPN in African 
American patients in E5103 
We previously reported common demographic 
predictors of TIPN in E5103 and that AAs in the parent 
trial were markedly more likely to experience both 
grade 2-4 (HR=2.1; P-value= 5.6 x 10-16) and grade 3-4 
(HR=2.6; P-value= 1.1 x 10-11) TIPN when compared 
with other races.[5] In the subgroup of previously genome 
wide genotyped AA patients in E5103, 39.1% experienced 
grade 2-4 TIPN and 16.6% experienced grade 3-4 TIPN 
(Figure 1). In this analysis, we evaluated covariates for 
Figure 1: CONSORT diagram for E5103.
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the population of AAs that underwent WES. Significant 
covariates in the grade 3-4 TIPN analysis included study 
arm, PC4 and PC9. Significant covariates in the grade 2-4 
TIPN analysis included BSA, arm, PC2 and PC7. 
Top associations for whole exome sequencing in 
E5103
In total, 583,362 variants were identified. After 
removing variants with missing rate > 20% and those 
which were monomorphic, 219,607 variants were used 
for annotation by ANNOVAR. 43,084 rare and predicted 
to be deleterious, variants were retained for gene-based 
analyses. 24 samples with missing rates > 30% were 
excluded in addition to 9 samples which did not have 
sufficient DNA for sequencing. A total of 180 samples 
(121 with grade 2-4 TIPN, 56 with grade 3-4 TIPN and 59 
controls) passed QC and were evaluable in further analysis 
(Figure 1). Gene-based analysis required at least 2 variants 
to be retained in a given gene for it to be included in the 
analysis. For the grade 3-4 analysis, 7,260 genes had more 
than 2 variants, thus setting the threshold for significance 
at p-value < 6.89 x10-6. For the Grade 2-4 analysis, 8,958 
genes had more than 2 variants, thus setting the threshold 
for significance at p-value < 5.58 x10-6. The results of 
the gene-based association analyses are shown in Table 
1 and Figure 2. Five genes had p-value < 10-4 for grade 
3-4 TIPN. Three genes had a p-value < 10-4 for grade 2-4 
TIPN. 
For grade 3-4 TIPN, the top association was 
with SET binding factor 2 (SBF2) and was statistically 
significant for an increased risk (p-value=4.35 x10-6). 
Five mutations were predicted to be deleterious in SBF2 
(Figure 3 and Table 2). These 5 mutations in SBF2 were 
subsequently confirmed using Taqman-based assays. 
When comparing the estimated frequency of TIPN using 
the relative likelihood of an event, those patients who 
Table 1: Top genes associated with TIPN in the AA population from E5103
Gene
Grade 3-4 TIPN Grade 2-4 TIPN
P-value P-value
SBF2 4.84E-06 3.94E-05
OR51B6 5.08E-05 1.80E-05
SLCO2A1 7.37E-05 1.31E-03
ABCA2 9.29E-05 5.40E-04
MSH5 9.48E-05 1.21E-03
ZZEF1 2.33E-04 5.15E-03
POLR3E 2.86E-04 3.43E-04
GNL2 3.94E-04 4.99E-04
LRP3 4.83E-04 6.92E-05
WDR72 5.91E-04 2.80E-03
RGL3 6.19E-04 8.71E-04
SEPT12 6.77E-04 2.58E-03
CCER2 6.92E-04 2.00E-03
SH3RF2 7.17E-04 5.79E-04
POLR1A 7.67E-04 1.74E-03
C2orf44 8.20E-04 7.02E-03
PARP1 8.41E-04 2.87E-03
CNTROB 3.53E-03 3.64E-04
EXOC3L4 5.95E-03 4.68E-04
PLEKHM2 9.17E-03 5.59E-04
MTX3 5.24E-03 7.90E-04
NMRAL1 1.26E-02 7.98E-04
GLIS2 3.06E-02 8.08E-04
HAUS5 2.11E-03 9.02E-04
PYGM 4.54E-03 9.45E-04
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carried any of the five deleterious mutations in SBF2 
had a markedly increased risk of TIPN as compared with 
those who did not carry a variant and had grade 2-4 TIPN 
(OR=3.26) or grade 3-4 TIPN (OR=5.09); Figure 4. No 
genes were significantly associated with grade 2-4 TIPN. 
DISCUSSION
TIPN is a major complication for many cancer 
survivors. Unfortunately, there are few identified indicators 
that can predict whether an individual will develop TIPN. 
We previously demonstrated that a genetically defined 
group of AAs in E5103, receiving a commonly used dose 
and schedule for paclitaxel, had a markedly increased risk 
of grade 2-4 TIPN (HR=2.1; p=5.6×10-16) and grade 3-4 
TIPN (HR=2.6; p=1.1×10-11) when compared with other 
races.[5] In the current study, we have employed WES in 
a subset of the E5103 AA subsample and identified a gene, 
Table 2: Total counts of each rare variant in SBF2  
SNP
Grade 3-4 TIPN Grade 2-4 TIPN Controls
(N=56)* (N=121)* (N=59)*
rs149501654 2 2 0
rs117957652 1 2 0
rs141368249 2 3 0
rs146987383 0 1 0
rs7102464 7 10 3
 *Number of samples passed QC and were evaluable for final analysis
Figure 2: Manhattan plot (A) for Grade 3-4 TIPN from AA patients in ECOG-5103. X-axis indicates the chromosomal position of each 
gene analyzed; Y-axis denotes magnitude of the evidence for association, shown as –log
10
(p-value); Each dot represents an evaluable gene. 
(B) Grade 2-4 TIPN from AA patients in ECOG-5103. X-axis indicates the chromosomal position of each gene analyzed; Y-axis denotes 
magnitude of the evidence for association, shown as –log
10
(p-value); Each dot represents an evaluable gene. The dashed line indicates the 
genome-wide significance threshold. 
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SBF2, with a higher burden of rare deleterious variants 
among individuals developing grade 3-4 TIPN. 
SBF2 is on chromosome 11p15 and is a member of 
the myotubularin–related protein family. SBF2 encodes 
for a gene that, when mutated, is known to be associated 
with a subtype of Charcot-Marie-Tooth (CMT), a known 
hereditary form of polyneuropathy that develops in 
adolescence, early adulthood, or middle age. CMT is a 
progressive motor and sensory neuropathy and is the most 
common form of hereditary neuropathy. A case report 
previously described that a patient with ovarian cancer 
who had pre-existing peripheral neuropathy secondary 
to CMT immediately developed grade 3 sensory and 
motor neuropathy after a single dose of carboplatin and 
paclitaxel.[18] Mutations in SBF2 cause Type 4B CMT, 
the only type of CMT with an autosomal recessive pattern 
of inheritance and characterized by axonal degeneration 
and myelin outfolding.[19]
Genes contributing to CMT have been previously 
reported to be associated with TIPN.[7, 8] We previously 
performed a genome wide association study (GWAS) to 
identify common variants associated with TIPN among 
AA in E5103.[5] A potential association between FCAMR 
and a decreased risk of grade 2-4 TIPN was observed 
(Supplemental Figure 1). Baldwin et al, reported their 
results from a GWAS of CALGB40101 and the top 
associations were with SNPs in FDG4, EPHA5, and 
FZD3; although the first two did not meet genome wide 
significance.[7] The FGD4 variant from the CALGB40101 
EA discovery set was replicated in a small cohort of 
AA patients.[7] Both FGD4 and SBF2 are known to be 
associated with subtype 4 CMT.[20] Few prior studies 
have tested for the effect of rare variants across the exome 
or genome on TIPN. Beutler et al., performed massively 
parallel sequencing across 119 EA TIPN patients, focusing 
on 49 candidate genes felt to be important in the CMT 
pathway.[8] In that study, several SNPs in AREGF10 had 
a modest association with TIPN. In total, these studies 
provide substantial evidence that genes in the CMT 
pathway contribute to the risk of TIPN. 
There were no statistically significant associations 
identified in the grade 2-4 TIPN analysis. Other top genes 
Figure 3: Comprehensive representation of the 5 rare variants detected in the cases from AA patients with grade 3-4 
TIPN. The X-axis denotes the chromosomal location of each mutation and the Y-axis denotes the number of patients with TIPN that 
had a given mutation. Each pie-wedge shape & onentation represents the program prediction method and the color represents the type of 
mutation. The size of the pie represents the CADD score. 
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in both analyses (Table 1) included established drug 
transporters (SLCO2A1 and ABCA2; ranked #3 and #4, 
respectively), DNA mismatch repair genes (MSH5 and 
PARP1; ranked #5 and #17, respectively), and a gene 
encoding for a microtubule binding complex (HAUS5; 
ranked #24). 
Strengths of this study include the use of cutting-
edge, expansive genomic sequencing in the context 
of a large trial in an under-represented population of 
patients who have increased vulnerability to a potentially 
irreversible therapy-induced toxicity. This correlative 
study evaluated patients that received a uniform dose 
and schedule of paclitaxel within the context of a large, 
randomized, phase III breast cancer clinical trial [21] 
with rigorous data collection. Another strength of 
our study was the focus on a genetically defined AA 
Figure 4: Estimated frequency of TIPN for the entire AA population (black bar), those who have no deleterious 
mutations in SBF2 (light gray bar), and those who carry any SBF2 deleterious mutations (dark gray bar). Each colored 
bar represents the estimated frequency of TIPN based on the relative likelihood of an event. The percentage value above each bar represents 
the estimated likelihood of a patient with that variant or genotype experiencing TIPN. The percentage value on the x-axis represents the 
fraction of the AA population with that specific genotype. Top graph represents grade 2-4 TIPN and bottom graph represents grade 3-4 
TIPN.
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population, a subgroup with a substantially increased 
risk for TIPN in E5103. Unfortunately many of the large 
clinical trials across the United States that have captured 
high-throughput genomic data have substantially under-
represented racial minorities [22, 23]. This correlative 
study represents one of the largest pharmacogenetic studies 
to date using WES with a focus on genetically determined 
patients of African descent. This dataset, then, allowed for 
the direct, rather than the typical inferential application 
of results, to the AA population. The implementation of 
massively parallel sequencing across the exome allowed 
for a comprehensive and unbiased evaluation of rare 
variants to discover the most important genes associated 
with TIPN. Thus, the discovery of a gene in a pathway 
known to have implications in a form of hereditary 
neuropathy has immediate translational implications. 
There are also several weaknesses of this study. 
First, the study was limited to the exome and therefore 
could not detect potentially important genetic variants in 
the non-coding region of the genome. In addition, since 
only genes having at least two retained variants were 
included in the analysis, approximately 65% of the genes 
in the genome were not statistically evaluated in this 
study. Another limitation of this study was the use of the 
CTCAE grading scale to define the cases of TIPN. There 
are data to support that use of patient reported outcomes 
and more detailed clinical examinations are superior and 
thus should be considered for future validation biomarker 
studies.[24] The sample size of this study is modest and is 
therefore only powered to detect association with genes 
having multiple variants with large effects on TIPN risk. 
To rigorously evaluate all genes in the genome for their 
association with TIPN risk would require a sample many 
orders of magnitude larger than ECOG-5103 so as to 
have a sufficient number of AA cases with TIPN and AA 
controls without evidence of neuropathy.
Understanding which patients might be at increased 
risk of severe and potentially irreversible toxicities is a 
critical step toward improved patient counseling and 
monitoring. When competing drug regimens exist, 
drugs with different toxicities may be selected on a more 
personalized basis. Specifically, while clinicians might 
be most concerned about the rare risk of anthracycline-
induced cardiac toxicity for a general population, the risk 
for a non-taxane based regimens might be more favorable 
for those at increased risk of severe TIPN.[25] Further, 
a marker for increased risk might help make a nuanced 
determination for selection of a taxane (i.e. docetaxel) 
with a slightly lower risk of TIPN even at the cost of 
increased risk for competing toxicities. There are also 
situations where the anticipated benefit from a taxane-
based regimen is marginal and a marker of increased risk 
of TIPN might deter the patient from therapy altogether. 
Further work to understand the clinical impact of this 
biomarker on clinician and patient decision-making and 
implementation are critical next steps. The discovery 
of predictive genetic biomarkers might also point us in 
the direction of the underlying biological mechanism 
for this toxicity and subsequently lead to the therapeutic 
development for agents designed to either prevent or treat 
this toxicity. Importantly, risk based biomarkers allow for 
improved personalization of therapy with the promise of 
helping patients. 
MATERIALS AND METHODS
ECOG-5103 Overview
ECOG-5103 was a phase III adjuvant breast cancer 
trial that randomized 4994 patients with node positive 
or high-risk node negative breast cancer to intravenous 
doxorubicin and cyclophosphamide every 2 or 3 weeks 
(at discretion of treating physician) for four cycles (AC) 
followed by 12 weeks of weekly paclitaxel (P; 80 mg/m2) 
alone (Arm A) or to the same chemotherapy with either 
concurrent bevacizumab (Arm B) or concurrent plus 
sequential bevacizumab (Arm C)[21] .
Previous genome wide genotyping
Germline DNA from whole blood and companion 
clinical data were available from 3394 patients. This 
included 386 patients who were genetically determined 
to be of African descent (Figure 1). Genome wide SNP 
arrays (either Illumina HumanOmni1-Quad or Human 
OmniExpress) were performed in two distinct study 
subsets as described previously.[5, 26] A principal 
component analysis (PCA) was performed using 
Eigenstrat and reference data from 11 HapMap phase 
III populations to identify clusters using the first two 
eigenvectors computed using common SNPs from these 
two arrays. Both arrays were previously used to genotype 
a set of common samples; discrepancies between these two 
arrays were negligible[27]. Therefore, we have combined 
the two data sets to perform PCA. Samples clustering with 
those of African descent were used in these analyses.[5, 
26]
Case and control definitions 
Cases: Two definitions of TIPN were employed. 
A more stringent criteria limited cases to only those 
experiencing grade 3-4 TIPN (n=64) (Figure 1) as 
assessed by the Common Toxicity Criteria Adverse Events 
(CTCAE) version 3.0. A less stringent TIPN definition 
included as cases those experiencing grade 2-4 TIPN 
(n=151) (Figure 1). Under both definitions, cases included 
patients receiving at least one dose of paclitaxel and the 
neuropathy event occurred during treatment or within 3 
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months of the last dose of therapy.
Controls: Controls (n=62) (Figure 1) included 
patients who met all the following: 1). Received all 
planned doses of paclitaxel; 2). Had follow-up for at least 
3 months after the last dose of drug; 3). Did not meet any 
of the case definitions as outlined above; and 4). Had 
either paclitaxel or bevacizumab held or modified for any 
reason (i.e. disease progression or other toxicity).
Whole exome sequencing in E5103
Germline DNA samples were quantified by 
fluorometric methods (Qubit, LifeTechnologies, Eugene, 
USA). Library preparation was performed according to 
the manufacturer’s guidelines. Exomes were enriched 
from genomic DNA (50-100 ng) via Ion AmpliSeq™ 
Exome RDY kits. Libraries were subjected to magnetic 
bead-based clean up and quantified by qPCR prior to 
sequencing. Adapters and barcodes were incorporated 
during library construction, which allowed for two 
samples to be pooled per Ion PI™ chip. Templates were 
prepared on Ion Chef™ Systems then sequenced on 
Ion Proton™ Sequencers (LifeTechnologies) for 520 
flows. Typically sequencing runs generated 50-90M 
reads, yielding on average over 100X coverage of the 
exome with >90% uniformity. Exomes were aligned to 
the human genome version GRCh37.3. Variants (SNPs, 
indels, MNPs) were identified by the Torrent VariantCaller 
4.2 software. Libraries on average contained over 50,000 
variants. Variants with missing rates > 20% were filtered 
out of the dataset. Samples with missing rates > 30% were 
excluded. 
ANNOVAR (http://annovar.openbioinformatics.
org/en/latest/#reference) was used to annotate location, 
function and MAF of each variant. To focus on rare 
variants, only those meeting at least one of the following 
criteria were retained: 1). MAF ≤ 3% in ESP 6500 (http://
evs.gs.washington.edu/EVS/) AA population (primary); 
2). MAF ≤ 3% in both 1000G (http://www.1000genomes.
org/) EA and AA populations (secondary); 3). MAF ≤ 
3% in both ExAc (http://exac.broadinstitute.org/) African 
or Non-Finnish European populations (tertiary); or 4) 
novel variants that were reported by any of the reference 
datasets. Only SNPs defined by RefGene as one of 
the following were retained: frameshift substitution, 
nonsynonymous, stop gains, stop loss, or unknown. 
Retained SNPs were predicted to be deleterious by at least 
one of the following: 1). SIFT,[28] 2). POLYPHEN2, [29] 
or 3). CADD (with a score ≥10).[30] The genotypes of the 
identified deleterious SNPs were confirmed in this dataset 
with TaqMan SNP assays.
Statistical analysis
A gene-based case-control analysis (SKAT; http://
www.hsph.harvard.edu/skat/) was performed to identify 
genes associated with an increased risk of TIPN. Study 
arm, body surface area (BSA), and age were considered 
as covariates in this analysis. Although these samples 
were genetically defined as AA based on the common 
variants on the SNP arrays, we included the first 10 
principal components (PC1 to PC10) as covariates in the 
analysis to adjust for subtle population sub-structures 
often observed in AA samples.[31] Samples with grade 
2 TIPN were sequenced separately; therefore, a batch 
indicator was also included to adjust potential effect of 
different experiments. The p-value threshold was < 0.05 
for inclusion of covariates in the regression model. Only 
genes having at least two retained variants were included 
in the gene-based analysis. The significance threshold for 
the SKAT analysis was determined by correcting for the 
number of genes tested in each of the TIPN models. Given 
the rarity of the individual variants as well as the focus on 
a gene-based analysis, we do not report individual odds 
ratios for each variant on TIPN risk.
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